Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 3 years, the average EPS without NRI Growth Rate was 54.00% per year.
During the past 5 years, the average EPS without NRI Growth Rate was -46.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 7 years, the highest 3-Year average EPS without NRI Growth Rate of Ginkgo Bioworks Holdings was 54.00% per year. The lowest was -818.20% per year. And the median was -201.65% per year.
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Ginkgo Bioworks Holdings 3-Year EPS without NRI Growth Rate Related Terms
DNA vs PBYI, CCCC, RLMD: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Ginkgo Bioworks Holdings's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ginkgo Bioworks Holdings 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ginkgo Bioworks Holdings's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Ginkgo Bioworks Holdings's 3-Year EPS without NRI Growth Rate falls into.
Ginkgo Bioworks Holdings 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 54.00% mean?
Ginkgo Bioworks Holdings (DNA) has a 3-Year EPS without NRI Growth Rate of 54.00% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Ginkgo Bioworks Holdings and its competitors. According to the industry distribution chart, Ginkgo Bioworks Holdings ranks #147 out of 1160 companies in the Biotechnology industry, placing it in the top 12.7%.
Is Ginkgo Bioworks Holdings' 3-Year EPS without NRI Growth Rate too high?
Ginkgo Bioworks Holdings' current 3-Year EPS without NRI Growth Rate is 54.00%. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 16.05. Ginkgo Bioworks Holdings' value of 54.00% is 236.4% above this industry median. Based on the distribution chart, Ginkgo Bioworks Holdings ranks #147 out of 1160 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Ginkgo Bioworks Holdings has a GF Score™ of 62/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ginkgo Bioworks Holdings' 3-Year EPS without NRI Growth Rate compare to PBYI and CCCC?
According to the Biotechnology industry distribution chart, Ginkgo Bioworks Holdings ranks #147 out of 1160 companies for 3-Year EPS without NRI Growth Rate. This places Ginkgo Bioworks Holdings in the top 13% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 16.05. Ginkgo Bioworks Holdings' value of 54.00% is 236.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.05, based on 1,160 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ginkgo Bioworks Holdings's current 3-Year EPS without NRI Growth Rate of 54.00% is 236.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Ginkgo Bioworks Holdings and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ginkgo Bioworks Holdings's current 3-Year EPS without NRI Growth Rate is 54.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ginkgo Bioworks Holdings stock overvalued right now?
Based on GuruFocus' analysis, Ginkgo Bioworks Holdings (DNA) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.91, compared to a current price of $7.03 — trading 19% above its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 54.00% and 236.4% above the Biotechnology industry median of 16.05. Ginkgo Bioworks Holdings' overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Ginkgo Bioworks Holdings (DNA), the current 3-Year EPS without NRI Growth Rate is 54.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ginkgo Bioworks Holdings (DNA) Overvalued in 2026?
Based on GuruFocus' analysis, Ginkgo Bioworks Holdings stock appears to be overvalued.
The current stock price of $7.03 is trading 19% above its estimated GF Value™ of $5.91.
GuruFocus considers Ginkgo Bioworks Holdings to be Modestly Overvalued.
Key valuation signals for DNA:
3-Year EPS without NRI Growth Rate: 54.00%
GF Value™: $5.91 vs. price of $7.03 (19% above fair value)
Industry Position: 236.4% above the Biotechnology median (#147 of 1160)
No single metric tells the full story. See the DNA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
62GF Score
Get the complete analysis for DNA
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DNA has been successfully added to your 
